Loading
Cardiac Valve Diseases and Treatments / Cancer Related Molecular Mechanisms Research · Journal article
Genes · July 15, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review summarizing mechanistic, preclinical, and observational evidence on long non-coding RNAs (lncRNAs) in coronary heart disease pathophysiology, diagnosis, and therapeutic potential. The source describes regulatory roles of specific lncRNAs (MIAT, MALAT1, ANRIL, H19) in cardiomyocyte apoptosis, oxidative stress, angiogenesis, and fibrosis, and identifies several as potential biomarkers for adverse events; however, it emphasizes that clinical translation remains limited by safety, delivery, and validation challenges. This is an exploratory synthesis of the field rather than a trial or meta-analysis, and does not provide efficacy or safety data suitable for clinical decision-making.
Narrative review. Patients with coronary heart disease or coronary artery disease (conceptual; no primary studies reported)..
Selected lncRNAs (MIAT, MALAT1, ANRIL, H19) influence inflammatory processes, vascular smooth muscle cell proliferation, hypoxia responses, and cardiac fibrosis in coronary heart disease. Molecules MALAT1, MIAT, LIPCAR, and HCG11 are identified as candidates with potential diagnostic and prognostic value, including prediction of major adverse cardiovascular events and no-reflow phenomenon after percutaneous coronary intervention. Contemporary lncRNA-targeting therapies include antisense oligonucleotides, siRNAs, and CRISPR/Cas9 genome-editing technologies.
Therapeutic strategies presented as preclinical; no clinical trial outcomes, adverse event rates, or efficacy data reported. Molecules MALAT1, MIAT, LIPCAR, and HCG11 are identified as candidates with potential diagnostic and prognostic value, including prediction of major adverse cardiovascular events and no-reflow phenomenon after percutaneous coronary intervention.
Clinicians should recognize that while lncRNAs represent a mechanistically interesting avenue for precision medicine in coronary disease, no lncRNA-based diagnostic or therapeutic interventions have yet demonstrated sufficient clinical validation for adoption in routine practice. Current evidence supports continued research rather than clinical implementation.
This is a narrative review synthesizing mechanistic and preclinical evidence about lncRNAs in coronary disease; it raises research questions and presents existing knowledge rather than testing a hypothesis or reporting new clinical data.
As stated by the source record.
Clinicians should recognize that while lncRNAs represent a mechanistically interesting avenue for precision medicine in coronary disease, no lncRNA-based diagnostic or therapeutic interventions have yet demonstrated sufficient clinical validation for adoption in routine practice. Current evidence supports continued research rather than clinical implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Long non-coding RNAs (lncRNAs) constitute an important group of regulatory RNA molecules involved in the control of gene expression at the epigenetic, transcriptional, and post-transcriptional levels. In recent years, their crucial role in the pathophysiology of cardiovascular diseases, particularly coronary heart disease, has become increasingly evident. The aim of this review is to present current knowledge regarding the mechanisms of lncRNA action in the cardiovascular system, their involvement in the molecular processes associated with myocardial ischaemia, and their potential diagnostic and therapeutic applications. We discuss the molecular mechanisms responsible for the regulation of cardiomyocyte apoptosis, oxidative stress, mitochondrial dysfunction, angiogenesis, coronary vessel remodelling, and cardiac fibrosis. Particular attention is paid to selected lncRNAs involved in coronary heart disease, including MIAT, MALAT1, ANRIL, and H19, which influence inflammatory processes, vascular smooth muscle cell proliferation, responses to hypoxia, and cardiac fibrosis. The potential of lncRNAs as diagnostic and prognostic biomarkers in coronary artery disease is also discussed. Current evidence suggests that molecules such as MALAT1, MIAT, LIPCAR, and HCG11 may have considerable diagnostic and prognostic value, including for predicting major adverse cardiovascular events and the no-reflow phenomenon following percutaneous coronary intervention. Furthermore, contemporary therapeutic strategies targeting lncRNAs are presented, including antisense oligonucleotides, siRNAs, and CRISPR/Cas9 genome-editing technologies. Despite promising preclinical findings, the clinical application of lncRNA-based therapies remains limited by challenges related to safety, delivery of therapeutic molecules, and translation of experimental findings into clinical practice. Nevertheless, lncRNAs represent a promising avenue for the development of precision medicine and may play an important role in the future diagnosis and treatment of cardiovascular diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.